FDA Rejection Of Amgen Drug Does Nothing To Change Baird's Outlook On The Stock
August 26, 2016 at 09:57 AM EDT
Amgen, Inc. (NASDAQ: AMGN) has received a CRL [complete response letter] in relation to Parsabiv, a calcimimetic under review by the ...
